Interstitial lung disease (ILD) contributes significantly to morbidity and mortality in connective tissue disease (CTD). Early detection and accurate diagnosis are essential for informing treatment decisions and prognosis in this setting. Clear guidance on CTD-ILD screening, however, is lacking. To establish recommendations for CTD-ILD screening based on the current evidence. Following an extensive literature research and evaluation of articles selected for their recency and relevance to the characterization, screening, and management of CTD-ILD, an expert panel formed by six pulmonologists from the Portuguese Society of Pulmonology, six rheumatologists from the Portuguese Society of Rheumatology, and six radiologists from the Portuguese Society of Radiology and Nuclear Medicine participated in a multidisciplinary discussion to produce a joint statement on screening recommendations for ILD in CTD. The expert panel achieved consensus on when and how to screen for ILD in patients with systemic sclerosis, rheumatoid arthritis, mixed connective tissue disease, Sjögren syndrome, idiopathic inflammatory myopathies and systemic lupus erythematous. Despite the lack of data on screening for CTD-ILD, an expert panel of pulmonologists, rheumatologists and radiologists agreed on a series of screening recommendations to support decision-making and enable early diagnosis of ILD to ultimately improve outcomes and prognosis in patients with CTD.
1 March 2013 in Revista Española de Enfermedades Digestivas
CPCentro Hospitalar de Vila Nova de Gaia/Espinho Serviço de Anatomia Patológica
Centro Hospitalar de Vila Nova de Gaia/Espinho Serviço de Anatomia Patológica
+1
A avaliação de resposta ao tratamento sistémico no CPNPCm pode ser desafiante, particularmente quando se utiliza imunoterapia, devido à possibilidade de padrões atípicos de resposta. Descrevemos um caso de adenocarcinoma pulmonar metastático sob imunoterapia e quimioterapia com aparente resposta dissociada em nódulo pulmonar, cuja biópsia da lesão não respondedora revelou um diagnóstico histológico diferente do tumor primário. Quando existe discrepância no tipo de resposta ao tratamento sistémico de duas lesões alvo diferentes, é importante ponderar a possibilidade de se tratar de um segundo tumor primário. A confirmação do diagnóstico histopatológico e/ou molecular é crucial para o (re)estadiamento, orientação de tratamento e prognóstico do doente.